|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75(Suppl 1): 191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fong KM, Sekido Y, Gazdar AF and Minna JD:
Lung cancer. 9: Molecular biology of lung cancer: clinical
implications. Thorax. 58:892–900. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aviel-Ronen S, Blackhall FH, Shepherd FA
and Tsao MS: K-ras mutations in non-small-cell lung
carcinoma: a review. Clin Lung Cancer. 8:30–38. 2006.
|
|
5
|
Haura EB, Camidge DR, Reckamp K, et al:
Molecular origins of lung cancer: prospects for personalized
prevention and therapy. J Thorac Oncol. 5(Suppl 3): S207–S213.
2010. View Article : Google Scholar
|
|
6
|
Huff V: Wilms’ tumours: about tumour
suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer.
11:111–121. 2011.
|
|
7
|
Shackelford DB and Shaw RJ: The LKB1-AMPK
pathway: metabolism and growth control in tumour suppression. Nat
Rev Cancer. 9:563–575. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soo Hoo L, Zhang JY and Chan EK: Cloning
and characterization of a novel 90 kDa ‘companion’ auto-antigen of
p62 overexpressed in cancer. Oncogene. 21:5006–5015. 2002.
|
|
9
|
Junttila MR, Puustinen P, Niemelä M, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khanna A, Pimanda JE and Westermarck J:
Cancerous inhibitor of protein phosphatase 2A, an emerging human
oncoprotein and a potential cancer therapy target. Cancer Res.
73:6548–6553. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Boehm JS, Hession MT, Bulmer SE and Hahn
WC: Transformation of human and murine fibroblasts without viral
oncoproteins. Mol Cell Biol. 25:6464–6474. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Drayton S, Rowe J, Jones R, et al: Tumor
suppressor p16INK4adetermines sensitivity of human cells
to transformation by cooperating cellular oncogenes. Cancer Cell.
4:301–310. 2003.
|
|
13
|
Westermarck J and Hahn WC: Multiple
pathways regulated by the tumor suppressor PP2A in transformation.
Trends Mol Med. 14:152–160. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Côme C, Laine A, Chanrion M, et al: CIP2A
is associated with human breast cancer aggressivity. Clin Cancer
Res. 15:5092–5100. 2009.PubMed/NCBI
|
|
15
|
Dong QZ, Wang Y, Dong XJ, et al: CIP2A is
overexpressed in non-small cell lung cancer and correlates with
poor prognosis. Ann Surg Oncol. 18:857–865. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang LP, Adelson ME, Mordechai E and
Trama JP: CIP2A expression is elevated in cervical cancer. Cancer
Biomark. 8:309–317. 2010.PubMed/NCBI
|
|
17
|
Vaarala MH, Väisänen MR and Ristimäki A:
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer
Res. 29:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen KF, Liu CY, Lin YC, et al: CIP2A
mediates effects of bortezomib on phospho-Akt and apoptosis in
hepatocellular carcinoma cells. Oncogene. 29:6257–6266. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Beckebaum S, Iacob S, Klein CG, et al:
Assessment of allograft fibrosis by transient elastography and
noninvasive biomarker scoring systems in liver transplant patients.
Transplantation. 89:983–993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ren XS, Sato Y, Harada K, et al:
Activation of the PI3K/mTOR pathway is involved in cystic
proliferation of cholangiocytes of the PCK rat. PLoS One.
9:e876602014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Alayev A and Holz MK: mTOR signaling for
biological control and cancer. J Cell Physiol. 228:1658–1664. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kim DH, Sarbassov DD, Ali SM, et al: mTOR
interacts with raptor to form a nutrient-sensitive complex that
signals to the cell growth machinery. Cell. 110:163–175. 2002.
View Article : Google Scholar : PubMed/NCBI
|
